Clinical trials: Dementia Mild
Alzheimer's Disease
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
A Phase II clinical research study to evaluate the efficacy and safety of two different dose levels of an injectable investigational treatment (ACC-001) in subjects with Mild-to-Moderate Alzheimer's disease.
- Trial name
- ACCTION (NCT01284387)
- Testing
- ACC-001 (vanutide cridificar)
- Where
- 25 sites in United States
- Volunteers
- 126 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer's Disease, Cognitive Impairment
Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions
The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild Alzheimer's disease (AD), memory complaint patients…
- Trial name
- NCT00814346
- Testing
- EGb761®
- Where
- 8 sites in France
- Volunteers
- 49 people
- Sponsor
- Ipsen
Alzheimer's Disease, Dementia
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or…
- Trial name
- NCT01969123
- Testing
- Drug: EVP-6124
- Where
- 82 sites in United States, Australia and 10 more
- Volunteers
- 474 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer's Disease
A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
This study aims to evaluate the safety, tolerability and pharmacodynamics of intravenous administration of SHR-1707 In patients with mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease.
- Trial name
- NCT05681819
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Early Alzheimer's Disease
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical…
- Trial name
- Clarity AD (NCT03887455)
- Testing
- Lecanemab IV, Lecanemab SC
- Where
- 247 sites in United States, Australia and 12 more
- Volunteers
- 1,906 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
The study is designed to investigate the safety and efficacy of SB-742457 when added to stable donepezil treatment in subjects with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00710684
- Testing
- SB-742457 15mg, SB-742457 35mg, donepezil 5-10mg
- Where
- 102 sites in United States, Argentina and 7 more
- Volunteers
- 682 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers
Study to Assess Brain Uptake and Safety of AH110690 (18F) Injection in Subjects with Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers.
- Trial name
- ALZ201 (NCT00785759)
- Testing
- AH110690 (18F) Injection
- Where
- Norway
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Alzheimer's Disease
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
To study the safety of LY2062430 in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers.
- Trial name
- NCT00329082
- Testing
- LY2062430
- Where
- 6 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Mild Cognitive Impairment
Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
- Trial name
- REPHRASE (NCT05107882)
- Where
- 7 sites in United States, Canada
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- Optina Diagnostics Inc.
Mild Cognitive Impairment (MCI), Mild Dementia
Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
A randomized, double-blind, placebo-controlled, dose-finding Phase 2a clinical trial will be conducted to evaluate the efficacy and safety of KDS2010 in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease…
- Conditions
- Mild Cognitive Impairment (MCI), Mild Dementia, Alzheimer's Disease
- Trial name
- NCT07027072
- Testing
- KDS2010
- Where
- 8 sites in South Korea
- Volunteers
- 114 people
- Sponsor
- NeuroBiogen Co., Ltd
Mild Cognitive Impairment
A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting
This study will be conducted to evaluate the rate of Alzheimer's disease conversion differences between high-risk mild cognitive impairment (MCI) and low-risk MCI.
- Trial name
- CONCORDE (NCT03448445)
- Testing
- Usual care setting
- Where
- 16 sites in South Korea
- Volunteers
- 201 people
- Sponsor
- Eisai Korea Inc.
Alzheimer Disease
Study of BHV-4157 in Alzheimer's Disease
Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, were administered orally once daily.
- Trial name
- T2 Protect AD (NCT03605667)
- Testing
- troriluzole
- Where
- 44 sites in United States
- Volunteers
- 350 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Alzheimer's Disease
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
This study is a Phase 2b/3 clinical trial of a new candidate drug (T3D-959) to treat patients with mild-to-moderate Alzheimer's.
- Trial name
- NCT06964230
- Testing
- T3D-959
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- T3D Therapeutics, Inc.
Alzheimer Disease
Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization product+, in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00955409
- Testing
- ACC-001(3µg) + QS21, ACC-001(10µg) + QS21, ACC-001(30µg) + QS21
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
Alzheimer's Disease
Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease
The purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.
- Trial name
- NCT00130429
- Testing
- PYM50028
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Phytopharm
Alzheimer's Disease
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
The study tests the effect of the NeuroAD on Alzheimer patients' cognitive function. The NeuroAD uses non-invasive stimulation of both magnetic and cognitive training.
- Trial name
- NCT01825330
- Testing
- TMS and cognitive stimulation
- Where
- 10 sites in United States, Israel
- Volunteers
- 131 people
- Sponsor
- Neuronix Ltd
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the safety and efficacy of MABT5102A in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01343966
- Testing
- MABT5102A
- Where
- 92 sites in United States, Canada and 4 more
- Volunteers
- 448 people
- Sponsor
- Genentech, Inc.
Alzheimer's Disease
Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.
- Trial name
- NCT06199037
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Alzheimer's Disease
Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).
- Trial name
- STARBEAM (NCT02006641)
- Testing
- Idalopirdine
- Where
- 162 sites in United States, Argentina and 17 more
- Volunteers
- 858 people
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease, Dementia
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity.
- Trial name
- NCT06721156
- Testing
- MK-1167
- Where
- 72 sites in United States, Argentina and 7 more
- Volunteers
- 369 people
- Sponsor
- Merck Sharp & Dohme LLC